

October 13, 2008

CURRICULUM VITA
F. BLAINE HOLLINGER, M.D.

Baylor College of Medicine
One Baylor Plaza, MS BCM-385
Houston, Texas 77030

713-798-4454 (Office)
713-798-3490 (Fax)
blaineh@bcm.edu (e-mail)

Educational Background:

University of Kansas
University of Kansas School of Medicine

B.A. Degree, --(b)(6)-
M.D. Degree, 1962

Fellowships:

Exchange Fellow, University of Kansas
(Southampton, England)
Fellow, China Medical Board of New York, Inc.
(Philippines)
NIH Special Fellow, Department of Virology &
Epidemiology, Baylor College of Medicine,
Houston, Texas

1957 - 1958
1961 - 1962
1968 - 1970

Professional Experience:

Internship and residency training in Internal Medicine at
Univ. of Calif. Hosp. in San Francisco,
Univ. of Washington Affiliated Hosp. in Seattle, and
Univ. of Kansas Med. Center in Kansas City

1962 - 1966

Assistant Chief, Arbovirus Infections Unit, Center for
Disease Control, USPHS, Atlanta, Georgia

1966 - 1968

Board eligible in Internal Medicine

1969

Assistant Professor of Virology and Epidemiology
Baylor College of Medicine

1970 - 1973

Associate Professor of Virology and Epidemiology

1973 - 1978

Professor of Molecular Virology and Epidemiology

1978 - Present

Professor of Medicine

1981 - Present

Director, Hepatitis Immunodiagnostic Laboratory	1982 - 1988
Director, Virology Reference Laboratory for AIDS Clinical Trials Group (ACTG), NIH	1985 - 1992
Medical Director, VA Research Center on AIDS and HIV Infections	1988 - 1993
Virology Unit Director, Center for AIDS Research (CFAR)	1994 - 2004
Director, Eugene B. Casey Hepatitis Research Center	1988 - Present

Hospital Appointments:

The Methodist Hospital	1982 – Present
Ben Taub General Hospital	1984 – Present
Veterans Affairs Medical Center	1988 – Present
St. Luke’s Episcopal Hospital	2005 – Present

Professional Elected Societies:

American Association for the Study of Liver Diseases
 American College of Gastroenterology (Fellow)
 American Gastroenterological Association
 Infectious Diseases Society of America (Fellow)
 International Association for the Study of the Liver

Medical Societies:

Harris County Medical Society
 Texas Medical Association

Honors and Awards:

Phi Beta Kappa
Rhodes Scholar Candidate
Summerfield Scholar
Alpha Omega Alpha

------(b)(6)-----

American Men and Women of Science
Marquis Who's Who in South and Southwest
Who's Who in Texas
“Physician of the Year”, Excellence Recognition Award, American Liver Foundation, South Texas Chapter (2005)

National/International Service Activities:

1990 International Symposium on Viral Hepatitis and Liver Disease (Seventh Triennial Congress), Houston, Texas, April 4-8, 1990 (Chairman).
1991 Shanghai (China) International Symposium on Liver Cancer and Hepatitis, May 21-23, 1991 (Co-Chairman).
International Symposium on Active Immunization Against Hepatitis A, Vienna, Austria, January 27-29, 1992 (Chairman).
Superinfection of Hepatitis A in Chronic Hepatitis Patients, Singapore, March 18, 1994 (Chairman).
1996 Shanghai (China) International Symposium on Liver Cancer and Hepatitis, March 5-7, 1996 (Co-Chairman).
Plenary session (New Viruses), Saul Krugman Awards Panel, Breakfast Workshop, and Oral/Poster Presentation Committee for the 1996 International Symposium on Viral Hepatitis and Liver Disease (Ninth Triennial Congress), Rome, Italy, April 21-25, 1996 (Chairman/Moderator).
Third African International Congress of the African Association of Study of Liver Disease, Cairo, Egypt, March 2-6, 1998 (Co-Chairman).
World Health Organization Technical Consultations on Hepatitis C, Geneva, Switzerland, April 27-29, 1998 (Rapporteur).
Parallel session (Hepatitis C: Basic Virology and Immunology) for the 50th Annual Meeting and Postgraduate Course of the American Association for the Study of Liver Disease, Dallas, Texas, November 5-9, 1999 (Co-Moderator).
Plenary session (Hepatitis D, Prevention of Posttransfusion Hepatitis and New Hepatitis Viruses) for the International Symposium on Viral Hepatitis Beyond The Millenium, Leuven, Belgium, December 9-11, 1999 (Co-Moderator).
Fourth Shanghai (China) International Symposium on Liver Cancer and Hepatitis, September 23-26, 2000 (Co-Chairman).
Vaccination for all Life Stages Symposium, Barcelona, Spain, September 8-10, 2002 (Workshop Moderator).

11th International Symposium on Viral Hepatitis and Liver Disease, Sydney, Australia, April 6-10, 2003 (Co-Chairman).
 Hong Kong-Shanghai International Liver Congress, February 14-17, 2004 (Co-Chairman).
 Havrix® National Scientific Advisory Board Meeting, New York, NY, July 16-17, 2004 (Workshop Moderator).
 Biennial Conference of the Asian Pacific Association for the Study of the Liver (APASL), New Delhi, India, December 11-15, 2004 (Session Moderator).
 15th Conference of Asian Pacific Association for the Study of the Liver (APASL), Bali, Indonesia, August 18-21, 2005 (Co-Chairperson).
 16th Conference of Asian Pacific Association for the Study of the Liver (APASL), Manila, Philippines, March 5-8, 2006 (Member of Faculty).
 Shanghai-Hong Kong International Liver Congress, March 25-28, 2006 (Moderator and Speaker).
 Viral Hepatitis Research Foundation of Japan, 25th Anniversary, May 22, 2006 (Invited Lecturer).
 12th International Symposium on Viral Hepatitis and Liver Disease, Paris, July 1-5, 2006 (International Advisory Committee, Moderator and Speaker).
 80th Anniversary of Shanghai Medical College, Shanghai, China, September 26-October 1, 2007 (Moderator and Speaker).
 Hong Kong-Shanghai International Liver Congress 2008 (International Advisory Committee, Moderator and Speaker).

Committee Member/Chairman:

American Association for the Study of Liver Disease – Abstract Committee, 1992
 American Association for the Study of Liver Disease – Practice Guidelines Committee (member since 1998)
 American Association for the Study of Liver Disease – HCV – Pathogenesis and Immunology Review Committee (1999)
 American Association of Blood Banks - Transfusion Transmitted Diseases Committee (Consultant, 1985 to present)
 American Liver Foundation (South Texas Chapter) – Board Director (member since 2001)
 Baylor College of Medicine - Personnel Health Committee (member since 1988)
 Baylor College of Medicine - Conflict of Interest Committee (member since 1990)
 Baylor College of Medicine - Ad hoc Committee on AIDS (member since 1993)
 Food and Drug Administration (FDA), Chairman, Blood Products Advisory Committee, 1996-2000 (Special Government Employee since 1995)
 FDA, NHLBI and NIAID, Advisor and Consultant for program projects, grants and contracts related to hepatitis and AIDS research
 Hepatitis Foundation International, Past Board Director (member 1995-1998)
 Lions Eye Bank of Texas, Advisory Board Member, Executive Medical Committee
 National Library of Medicine, NIH, Past Member, Expert Group on Viral Hepatitis
 State of Texas, Past Member, Commissioner of Health's Task Force on AIDS,

Editorial Board:

European Journal of Clinical Microbiology and Infectious Diseases
Journal of Viral Hepatitis
Past Associate Editor, Hepatitis Knowledge-Base Project, Massachusetts Medical Society
Past Associate Editor, Journal of Infectious Diseases

Consulting Editor:

Annals of Internal Medicine
Gastroenterology
GUT
Hepatology
Infection and Immunity
Journal of the American Medical Association
Journal of Clinical Microbiology
Journal of Hepatology
Journal of Infectious Diseases
Journal of Medical Virology
Journal of Viral Hepatitis
Liver International
New England Journal of Medicine
Transfusion
Vaccine

Presentations and Consultantships (from 2002 to present):

1. Consultant, Transmissible Spongiform Encephalopathies Advisory Committee, Food and Drug Administration, Bethesda, MD, January 17, 2002.
2. Speaker, "Management of Occupational Bloodborne Hazards", Gastroenterology 2002: Best Practices, Omni Houston Hotel, Houston, TX, February, 15-16, 2002.
3. Chairman and Speaker, "Hepatitis C – East meets West", "Natural history of hepatitis C and factors contributing to cirrhosis", World Congress of Gastroenterology, Bangkok, Thailand, February 24 – March 1, 2002.
4. Consultant, Blood Products Advisory Committee Meeting, Food and Drug Administration, Bethesda, MD, March 14-15, 2002.
5. Consultant, Transfusion Transmitted Diseases Committee Meeting, American Association of Blood Banks, Bethesda, MD, March 16, 2002.
6. Moderator, "Fulminant Hepatic Failure", GI Reading Course, Baylor College of Medicine, Houston, TX, March 21, 2002.

7. Attendee, Hepatic Inflammation and Immunity 2002, Galveston, TX, March 23-24, 2002.
8. Consultant, Universal Data Collection Meeting, Hematology Branch, Centers for Disease Control and Prevention, Atlanta, GA, April 23, 2002.
9. Presenter, “Risk Management of Occupational Blood-Borne Hazards”, Michael E. DeBaKey Department of Surgery Grand Rounds, Baylor College of Medicine, May 22, 2002.
10. Attendee (Board Member), American Liver Foundation Bid for Life Dinner and Auction benefiting the South Texas Chapter, The Hotel Derek, Houston, TX, June 7, 2002.
11. Attendee, National Institutes of Health Consensus Development Conference, Management of Hepatitis C: 2002, Bethesda, Maryland, June 10-12, 2002.
12. Consultant, Blood Products Advisory Committee Meeting, Food and Drug Administration, Bethesda, MD, June 13-14, 2002.
13. Speaker, “Hepatitis B Vaccination – Unresolved Issues”, Vaccination for All Life Stages Symposium, Barcelona, Spain, September 8-10, 2002.
14. Chair, Plenary Session I – Crawling, Workshop Feedback, Vaccination for All Life Stages Symposium, Barcelona, Spain, September 8-10, 2002.
15. Speaker, “Hepatitis B Prevention: Overview of Global Strategies and Accomplishments”, Hepatitis Free Generation Fortnight Program, Cheng Si-yuan (China International) Hepatitis Research Foundation, Beijing, China, January 23, 2003.
16. Participant, “Ask the Experts Panel on Treatment”, 2003 National Hepatitis Coordinators Conference, Centers for Disease Control and Prevention, San Antonio, TX, January 27, 2003.
17. Consultant, Transfusion Transmitted Diseases Committee Meeting, American Association of Blood Banks, Bethesda, MD, February 22, 2003.
18. Speaker, “Hepatitis C and Renal Disease – An Update”, Gastroenterology 2003: Setting the Standard, Houston Inter-Continental Hotel, Houston, TX, March 7-8, 2003.
19. Plenary Speaker, “Unresolved Issues in Viral Hepatitis Prophylaxis”, 11th International Symposium on Viral Hepatitis and Liver Disease, Sydney, Australia, April 6-10, 2003.
20. Chairman, Site Visit Review of two laboratories, Food and Drug Administration, Bethesda, MD, May 23, 2003.

21. Participant, Hepatitis C Advisory Board, Amgen, Dallas, TX, November 1, 2003.
22. Participant, Hepsera Regional Consultancy Meeting, Gilead Sciences, Houston, TX, November 11, 2003.
23. Speaker, Hepatitis C, Cryoglobulinemia and Renal Disease, 1st Tokyo International Symposium on Hepatitis C Virus, Tokyo, Japan, December 2-6, 2003.
24. Speaker, “Risk Estimates and Management of Occupational Blood-Borne Hazards (HBV and HCV)”, The Hong Kong – Shanghai International Liver Congress 2004, Hong Kong, China, February 14-17, 2004.
25. Co-Chairman, The Hong Kong – Shanghai International Liver Congress 2004, Hong Kong, China, February 14-17, 2004.
26. Invigilator for the Young Investigator Award, The Hong Kong – Shanghai International Liver Congress 2004, Hong Kong, China, February 14-17, 2004.
27. Moderator, “Viral Hepatitis”, GI Reading Course, Baylor College of Medicine, Houston, TX, February 26, 2004.
28. Participant, Blood Products Advisory Committee Meeting, Houston, TX (via conference call) March 19, 2004.
29. Speaker, “Issues in the Treatment of Rheumatic Disease Patients Who Have Chronic Liver Disease, Baylor College of Medicine, Houston, TX, May 11, 2004.
30. Moderator, Workshop on “Implementing Hepatitis A Vaccination into the Childhood Immunization Schedule”, Havrix® National Scientific Advisory Board Meeting, New York, NY, July 16-17, 2004.
31. Consultant, Blood Products Advisory Committee meeting, Washington, D.C., July 22-23, 2004.
32. Invited Speaker, “Serological Course of Hepatitis B”, Blood Products Advisory Committee meeting, Washington, D.C., July 22-23, 2004.
33. Participant, AACC Committee, Tour of UCLA Westwood Medical Center Campus, Los Angeles, CA, September 13, 2004.
34. Presenter, Debate on “Should Hepatitis A Vaccine Be Given to All Adults” Infectious Disease Society of America (IDSA), Boston, MA, September 30, 2004.
35. Speaker, “Treatment Options”, Contemporary Concepts in Liver Disease and Transplantation, Hilton Americas, Houston, TX, November 12-13, 2004.

36. Speaker, "Is the Natural History of Hepatitis C Altered by Therapy?", Biennial Conference of the Asian Pacific Association for the Study of the Liver (APASL), New Delhi, India, December 11-15, 2004.
37. Abstract Reviewer, Viral Hepatitis, Biennial Conference of the Asian Pacific Association for the Study of the Liver (APASL), New Delhi, India, December 11-15, 2004.
38. Moderator, Hepatitis C (Session 5), Biennial Conference of the Asian Pacific Association for the Study of the Liver (APASL), New Delhi, India, December 11-15, 2004.
39. Member, Site Visit Committee, Laboratory of Plasma Derivatives, Division of Hematology, Office of Blood Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Washington, D.C., February 25, 2005.
40. Moderator, "Systemic Complication of Liver Disease", GI Reading Course, Baylor College of Medicine, Houston, TX, March 10, 2005.
41. Speaker, "Liver Test Abnormalities: Could It Be a Drug?", Gastroenterology 2005: Current Problems, Current Solutions, Baylor College of Medicine, Hilton Americas - Houston Hotel, Houston, TX, March 18-19, 2005.
42. Consultant, Transfusion Transmitted Diseases Committee Meeting, American Association of Blood Banks, Bethesda, MD., April 9, 2005.
43. Presenter, HBV Variants – An Overview, HIV/HBV Variants and HBsAg Mutants: Diagnostic Challenges for Immunoassays, Washington, D.C., May 23-24, 2005.
44. Panel Chairperson, HBV Panel Discussion, HIV/HBV Variants and HBsAg Mutants: Diagnostic Challenges for Immunoassays, Washington, D.C., May 23-24, 2005.
45. Presenter, Overview presentation on "Implementation of HBV DNA Testing", EPFA/PEI (European Plasma Fractionation Association and the Paul Ehrlich Institute) 12th NAT Workshop, Surveillance and Screening of Blood Borne Pathogens, Co-sponsored by the U.S. Food and Drug Administration (FDA) and held in conjunction with the XVIIIth meeting of the SoGAT (Standardisation of Genetic Amplification Technology), Natcher Facility, NIH Campus, Bethesda, MD, May 26-27, 2005.
46. Participant, Molecular Virology and Microbiology Departmental Faculty Retreat, Houston, TX, June 1, 2005.
47. Chairman, Transfusion Transmitted Diseases Lookback Subcommittee Meeting, American Association of Blood Banks, Bethesda, MD, July 20, 2005.

48. Consultant, Blood Products Advisory Committee Meeting, Washington, D.C., July 21, 2005.
49. Moderator, "Diagnostic Tests and Pitfalls", GI Reading Course, Baylor College of Medicine, Houston, TX, August 4, 2005.
50. Co-Chairperson, Meet the Expert, Diagnosis and Management of Liver Fibrosis, 15th Conference of Asian Pacific Association for the Study of the Liver (APASL), Bali, Indonesia, August 18-21, 2005.
51. Invited Speaker, "HBV Genetic Diversity and Its Impact on Diagnostic Assays", 15th Conference of Asian Pacific Association for the Study of the Liver (APASL), Bali, Indonesia, August 18-21, 2005.
52. Advisor, GlaxoSmithKline Vaccine-Preventable Hepatitis Editorial Advisory Board Meeting, Chicago, IL, September 15, 2005.
53. Consultant, Transfusion Transmitted Diseases Committee Meeting, American Association of Blood Banks, Bethesda, MD, November 5, 2005.
54. Invited Speaker, "Hepatitis B: Diagnosis, Treatment and Prevention", Baptist Lutheran Medical Center, Kansas City, MO, December 6, 2005.
55. Speaker, "The HCV/HIV Coinfected Patient: A Ticking Time Bomb?", Gastroenterology Update 2006, Baylor College of Medicine, The Hilton Houston Post Oak Hotel, Houston, TX, March 10-11, 2006.
56. Invited Speaker, "Predictors of Sustained Response to HCV Beyond Viral Kinetics", 16th Conference of the Asian Pacific Association for the Study of the Liver (APASL), Manila, Philippines, March 5-8, 2006.
57. Invited Speaker, "HCV Infection in Post-Renal Transplantation: Don't Treat", 16th Conference of the Asian Pacific Association for the Study of the Liver (APASL), Manila, Philippines, March 5-8, 2006.
58. Invited Speaker, "The HCV/HIV Coinfected Patient: A Ticking Time Bomb?", The Shanghai-Hong Kong International Liver Congress, Shanghai, China, March 25-28, 2006.
59. Consultant, Transfusion Transmitted Diseases Committee Meeting, American Association of Blood Banks, Bethesda, MD, May 31, 2006.
60. Invited Speaker, "The History of Viral Hepatitis Research Serendipity and the Scientific Process (and the socioeconomic importance of prevention and control)", 25th Anniversary of the Viral Hepatitis Research Foundation of Japan, Tokyo, Japan, May 22, 2006.

61. Co-Chairperson, Parallel Session “Genetic Diversity and Diagnostic Testing in HBV and HCV Infections”, 12th International Symposium on Viral Hepatitis and Liver Disease, Paris, France, July 1-5, 2006.
62. Invited Speaker, “An Overview of Genetic Diversity and its Impact on Diagnostic Assays”, 12th International Symposium on Viral Hepatitis and Liver Disease, Paris, France, July 1-5, 2006.
63. Co-Chairperson, Plenary Session “Hepatitis A and B Vaccination and Public Health”, 12th International Symposium on Viral Hepatitis and Liver Disease, Paris, France, July 1-5, 2006.
64. Consultant, Transfusion Transmitted Diseases Committee Meeting, American Association of Blood Banks, Bethesda, MD, July 13, 2006.
65. Speaker, “HCV Infection – Pre- and Post-Renal Transplantation”, Gastroenterology Update 2007, Baylor College of Medicine, The Hilton Houston Post Oak Hotel, Houston, TX, February 16-17, 2007.
66. Speaker, “Predictors of Sustained Response to HCV Beyond Viral Kinetics”, Gastroenterology Update 2007, Baylor College of Medicine, The Hilton Houston Post Oak Hotel, Houston, TX, February 16-17, 2007.
67. Consultant, Transfusion Transmitted Diseases Committee Meeting, American Association of Blood Banks, Bethesda, MD, February 12, 2007.
68. Moderator, “Non-Alcoholic Fatty Liver”, GI Reading Course, Baylor College of Medicine, Houston, TX, April 5, 2007.
69. Consultant, Transfusion Transmitted Diseases Committee Meeting, American Association of Blood Banks, Bethesda, MD, April 25, 2007.
70. Consultant, Transfusion Transmitted Diseases Committee Meeting, American Association of Blood Banks, Bethesda, MD, September 15, 2007.
71. Invited Speaker, “The History of Viral Hepatitis Research Serendipity and the Scientific Process (and the socioeconomic importance of prevention and control)”, 80th Anniversary of Shanghai Medical College, Fudan University, Shanghai, China, September 26-October 1, 2007.
72. Co-Chairperson, Round table session, Global Hepatitis A Meeting, Miami, FL, November 30-December 2, 2007.

73. Speaker, "HBV: Who to Treat and Who to Observe", The Baylor College of Medicine GI and Liver Course 2008, The Hilton Houston Post Oak Hotel, Houston, TX, February 1-2, 2008.
74. Consultant, Transfusion Transmitted Diseases Committee Meeting, American Association of Blood Banks, Bethesda, MD, March 7-8, 2008.
75. Moderator, "Hepatitis B & D", GI Reading Course, Baylor College of Medicine, Houston, TX, April 24, 2008.
76. Invited Speaker, "Occult hepatitis B: infection or detection?", Shanghai International Liver Congress 2008, Hong Kong, China, June 12-15, 2008.
77. Consultant, Transfusion Transmitted Diseases Committee Meeting, American Association of Blood Banks, Bethesda, MD, September 13, 2008.
78. Invited Speaker, "Acute Viral Hepatitis", 9th Annual International Hot Topics in Liver Disease Conference, The Houstonian Hotel, Houston, TX, October 3-4, 2008.
79. Attendee, National Institutes of Health Consensus Development Conference: Management of Hepatitis B, Bethesda, MD, October 20-22, 2008.

Bibliography:

1. Pavri KM, Singh KRP and Hollinger FB. Isolation of a new parainfluenza virus from a frugivorous bat, *Rousettus leschenaulti*, collected at Poona, India. *Am. J. Trop. Med. & Hyg.* 20:125-130, 1971.
2. Hollinger FB and Pavri KM. Bat parainfluenza virus: immunological, chemical, and physical properties. *Am. J. Trop. Med. & Hyg.* 20:131-138, 1971.
3. Hollinger FB, Sharp JT, Lidsky MD and Rawls WE. Antibodies to viral antigens in systemic lupus erythematosus. *Arthritis and Rheumatism* 14:1-11, 1971.
4. Hollinger FB, Vorndam V and Dreesman GR. Assay of Australia antigen and antibody employing double-antibody and solid-phase radioimmunoassay techniques and comparison with the passive hemagglutination methods. *J. Immunol.* 107:1099-1111, 1971.
5. Hersh T, Hollinger FB, Goyal RK, Grubb MN and Melnick JL. Australia antigen and antibody and alpha-fetoglobulin in hepatoma patients. *Int. J. Cancer* 8:259-263, 1971.
6. Hersh T, Melnick JL, Goyal RK and Hollinger FB. Nonparenteral transmission of viral hepatitis type B (Australia antigen-associated serum hepatitis). *N. Engl. J. Med.* 285:1363-1364, 1971.
7. Dreesman GR, Hollinger FB, McCombs RM and Melnick JL. Production of potent anti-Australia antigen sera of high specificity and sensitivity in goats. *Infection & Immunity* 5:213-221, 1972.
8. Hollinger FB, Goyal RK, Hersh T, Powell HC, Schulman RJ and Melnick JL. Immune response to hepatitis virus type B in Down's syndrome and other mentally retarded patients. *Am. J. Epidemiol.* 95:356-362, 1972.
9. Hollinger FB. Radioimmunoassay for detection of hepatitis-associated antigen (HBAg). In: Vyas GN, Perkins HA and Schmid R, eds. *Hepatitis and Blood Transfusion*. New York: Grune and Stratton, pp. 67-170, 1972.
10. Dreesman GR, Hollinger FB, Suriano JR, Fujioka RS, Brunschwig JP and Melnick JL. Biophysical and biochemical heterogeneity of purified hepatitis B antigen. *J. Virol.* 10:469-476, 1972.
11. Giorgini GL Jr, Hollinger FB, Leduc L, Issarescu S, George J, Blackman A and Thayer WR Jr. Radioimmunoassay detection of hepatitis type B antigen: a prospective study in blood donors and recipients. *JAMA* 222:1514-1518, 1972.

12. Melnick JL and Hollinger FB. Hepatitis Virology. In: Popper H and Schaffner F, eds. Progress in Liver Diseases, Vol. 4. New York: Grune and Stratton, pp. 345-365, 1972.
13. Dreesman GR, Hollinger FB and Melnick JL. Detection of hepatitis B antigen by counter-immunoelectrophoresis: Enhancing role of homologous serum diluents. Appl. Microbiol. 24:1001-1002, 1972.
14. Vorndam AV, Murphy BL, Hollinger FB and Maynard JE. Attempts to detect hepatitis B virus by negative hemadsorption assay (37329). Proc. Soc. Exp. Biol. & Med. 143:395-399, 1973.
15. Dreesman GR, Hollinger FB, McCombs RM and Melnick JL. Alteration of hepatitis B antigen (HB Ag) determinants by reduction and alkylation. J. Gen. Virol. 19:129-134, 1973.
16. Hollinger FB, Aach RD, Gitnick GL, Roche JK and Melnick JL. Limitations of solid-phase radioimmunoassay for HB Ag in reducing frequency of post-transfusion hepatitis. N. Engl. J. Med. 289:385-391, 1973.
17. Hollinger FB, Wasi C, Dreesman GR and Melnick JL. Subtyping of hepatitis B antigen by use of monospecific antibody-coated cells. J. Infect. Dis. 128:753-760, 1973.
18. Hollinger FB, Aach RD, Gitnick GL, Roche JK and Melnick JL. Varieties of HB Ag. N. Engl. J. Med. 290:461-463, 1974.
19. Adam E, Hollinger FB, Melnick JL, Duenas A and Rawls WE. Type B hepatitis antigen and antibody among prostitutes and nuns: A study of possible venereal transmission. J. Infect. Dis. 129:317-321, 1974.
20. Hollinger FB, Werch J and Melnick JL. A prospective study indicating that double-antibody radioimmunoassay reduces the incidence of post-transfusion hepatitis B. N. Engl. J. Med. 290:1104-1109, 1974.
21. Hollinger FB. Hepatitis Viruses. In: Rose NR and Friedman H, eds. Manual of Clinical Microbiology. Washington, D.C.: American Society for Microbiology, pp. 819-833, 1974.
22. Aach RD, Alter HJ, Hollinger FB, Holland PV, Lander JJ, Melnick, JL and Weiler JM. Risk of transfusing blood containing antibody to hepatitis-B surface antigen. Lancet 2:190-193, 1974.
23. Chairez R, Hollinger FB, Melnick JL and Dreesman GR. Biophysical properties of purified morphologic forms of hepatitis B antigen. Intervirology 3:129-140, 1974.

24. Chairez R, Hollinger FB, Brunschwig JP and Dreesman GR. Comparative biophysical properties of hepatitis B antigen, subtypes adw and ayw. *J. Virol.* 15:182-190, 1975.
25. Hollinger FB, Morrison M, Chairez R and Dreesman GR. Immunological and biophysical properties of hepatitis B antigen labeled by the chloramine-T and by the lactoperoxidase methods. *J. Immunol. Methods* 8:67-83, 1975.
26. Dreesman GR, Chairez R, Suarez M, Hollinger FB, Courtney RJ and Melnick JL. Production of antibody to individual polypeptides derived from purified hepatitis B surface antigen. *J. Virol.* 16:508-515, 1975.
27. Hopkins CC, Hollinger FB, Johnson RF, Dewlett HJ, Newhouse VF and Chamberlain RW. The epidemiology of St. Louis encephalitis in Dallas, Texas, 1966. *Am. J. Epidemiol.* 102:1-15, 1975.
28. Williams KH, Hollinger FB, Metzger WR, Hopkins CC and Chamberlain RW. The epidemiology of St. Louis encephalitis in Corpus Christi, Texas, 1966. *Am. J. Epidemiol.* 102:16-24, 1975.
29. Cabral GA, Chairez R, Marciano-Cabral F, Suarez M, Dreesman GR, Melnick JL and Hollinger FB. Cell-mediated immunity in guinea pigs to subunits derived from hepatitis B surface antigen. *Infection & Immunity* 12:564-570, 1975.
30. Melnick JL, Hollinger FB, Cabral GA and Dreesman GR. Possibility of a vaccine for viral hepatitis type B. *Medical Digest* 21:13-16, 1975.
31. Gyorkey F, Hollinger FB, Eknayan G, Mirkovic R, Dreesman GR, Gyorkey P, Voss WR and Melnick JL. Immune-complex glomerulonephritis, intranuclear particles in hepatocytes, and in vivo clearance rates in subhuman primates inoculated with HBsAg-containing plasma. *Exp. & Molec. Pathol.* 22:350-365, 1975.
32. Hollinger FB, Cabral GA, Dreesman GR and Melnick JL. Humoral and cellular immunity in guinea pigs to polypeptides derived from HBsAg-containing particles. In: *Develop. Biol. Standard.* (International Symposium on Viral Hepatitis, Milan, December 1974). Basel: S. Karger, Vol. 30, pp. 284-291, 1975.
33. Dreesman GR, Hollinger FB and Melnick JL. Biophysical and biochemical properties of purified preparations of hepatitis B surface antigen (HBsAg). *Am. J. Med. Sci.* 270:123-129, 1975.
34. Hollinger FB. Summary of Session 2: Hepatitis B Virus. In: *Develop. Biol. Standard.* (International Symposium on Viral Hepatitis, Milan, December 1974). Basel: S. Karger, Vol. 30, pp. 459-462, 1975.

35. Hollinger FB, Bradley DW, Maynard JE, Dreesman GR and Melnick JL. Detection of hepatitis A viral antigen by radioimmunoassay. *J. Immunol.* 115:1464-1466, 1975.
36. Hollinger FB, Dreesman G.R, Fields H and Melnick JL. HBcAg, anti-HBc, and DNA polymerase activity in transfused recipients followed prospectively. *Am. J. Med. Sci.* 270:343-348, 1975.
37. Melnick JL, Dreesman GR and Hollinger FB. Approaching the control of viral hepatitis type B. *J. Infect. Dis.* 133:210-229, 1976.
38. Duffy J, Lidsky MD, Sharp JT, Davis JS, Person DA, Hollinger FB and Min K-W. Polyarthrititis, polyarteritis and hepatitis B. *Medicine* 55:19-37, 1976.
39. Hollinger FB. Immunoradiometric assay differentiates type A viral hepatitis from type B. *Clin. Lab. Forum* 8:6, 1976.
40. Hollinger FB, Bradley DW, Dreesman GR and Melnick JL. Detection of viral hepatitis type A. *Am. J. Clin. Pathol.* 65:854-865 (Suppl.), 1976.
41. Bradley DW, Hollinger FB, Hornbeck CL and Maynard JE. Isolation and characterization of hepatitis A virus. *Am. J. Clin. Pathol.* 65:876-889 (Suppl.), 1976.
42. Melnick JL, Hollinger FB and Dreesman GR. Recent advances in viral hepatitis: part 1. *Southern Medical Journal* 69:468-475; 634-641, 1976.
43. Hollinger FB and Maynard JE. Recent diagnostic techniques for detecting hepatitis A virus and antibody. *Rush-Presbyterian-St. Luke's Medical Bulletin*, Vol. 15, No. 2, 1976.
44. Melnick JL, Hollinger FB and Dreesman GR. Viral hepatitis research leading towards control by vaccination. *Arch. Roum. Path. Exp. Microbiol.* 35:5-65, 1976.
45. Fields HA, Dreesman GR, Hollinger FB, Marciano-Cabral F, Gyorkey F and Melnick JL. Endogenous DNA polymerase-positive core particles from hepatitis-infected hepatocytes. *Intervirology* 6:224-238, 1975/76.
46. Hornbeck CL, Gravelle CR, Hollinger FB and Bradley DW. Agarose gel filtration of concentrated fecal extracts containing virus-like particles associated with hepatitis A. *Intervirology* 6:309-314, 1975/76.
47. Maynard JE, Bradley DW, Hornbeck CL, Fields RM, Doto IL and Hollinger FB. Preliminary serologic studies of antibody to hepatitis A virus in populations in the United States. *J. Infect. Dis.* 134:528-529, 1976.
48. Hollinger FB, Grandner JW, Nickel FR and Suarez M. Hepatitis B prevalence within a dental student population. *JADA* 94:521-527, 1977.

49. Skinhoj P, Mikkelsen F and Hollinger FB. Hepatitis A in Greenland: importance of specific antibody testing in epidemiologic surveillance. *Am. J. Epidemiol.* 105:140-147, 1977.
50. Melnick JL, Dreesman GR and Hollinger FB. Viral hepatitis. *Sci. Am.* 237:44-52, 1977.
51. Gyorkey F, Melnick JL, Mirkovic R, Cabral GA, Gyorkey P and Hollinger FB. Experimental carcinoma of liver in macaque monkeys exposed to diethylnitrosamine and hepatitis B virus. *J. Natl. Cancer Inst.* 59:1451-1467, 1977.
52. Fields HA, Hollinger FB, Desmyter J, Melnick JL and Dreesman GR. Biochemical and biophysical properties of hepatitis B core particles derived from Dane particles and infected hepatocytes. *Intervirology* 8:336-350, 1977.
53. Hollinger FB, and Chin T. The epidemiology of viral hepatitis. *The Methodist Hospital Journal*, October, 1977, pp. 10-13.
54. Cabral GA, Marciano-Cabral F, Funk GA, Sanchez Y, Hollinger FB, Melnick JL and Dreesman GR. Cellular and humoral immunity in guinea pigs to two major polypeptides derived from hepatitis B surface antigen. *J. Gen. Virol.* 38:339-350, 1978.
55. Hollinger FB, Gitnick GL, Aach RD, Szmuness W, Mosley JW, Stevens CE, Peters RL, Weiner JM, Werch JB and Lander JJ. Non-A, non-B hepatitis transmission in chimpanzees: a project of the Transfusion-Transmitted Viruses Study Group. *Intervirology* 10:60-68, 1978.
56. Szmuness W, Stevens CE, Ikram H, Much MI, Harley EJ and Hollinger FB. Prevalence of hepatitis B virus infection and hepatocellular carcinoma in Chinese-Americans. *J. Infect. Dis.* 137:822-829, 1978.
57. Aach RD, Lander JJ, Sherman LA, Miller WV, Kahn RA, Gitnick GL, Hollinger FB, Werch J, Szmuness W, Stevens CE, Kellner A, Weiner JM and Mosley JW. Transfusion-transmitted viruses: interim analysis of hepatitis among transfused and nontransfused patients. In: Vyas GN, Cohen SN and Schmid R, eds. *Viral Hepatitis*. Philadelphia: Franklin Institute Press, pp. 383-396, 1978.
58. Hollinger FB, Dreesman GR, Sanchez Y, Cabral GA and Melnick JL. Experimental hepatitis B polypeptide vaccine in chimpanzees. In: Vyas GN, Cohen SN and Schmid R, eds. *Viral Hepatitis*. Philadelphia: Franklin Institute Press, pp. 557-567, 1978.
59. Hollinger FB and Alter HJ. Summary of Workshop B-6: non-A/non-B hepatitis. In: Vyas GN, Cohen SN and Schmid R, eds. *Viral Hepatitis*. Philadelphia: Franklin Institute Press, pp. 697-702, 1978.

60. Hollinger FB and Graham DY. Viral hepatitis: types A, B, and non-A/non-B. *Drug Therapy* 8:39-55, 1978.
61. Hollinger FB. The hepatitis controversy: Environmental control of hepatitis B: how 'safe' is 'safe enough'? Why recommendations vary. *Med. Instrumentation* 13:56-58, 1979.
62. Ware A, Luby J, Cuthbert J and Hollinger FB. Hepatitis in HBsAg-negative kidney transplant recipients. In: Bianchi L, Gerok W, Sickinger K and Stalder GA, eds. *Virus and the Liver (Falk Symposium 28, International Congress of Liver Diseases, Basel, Switzerland, 1979)*. MTP Press Limited, pp. 277-283, 1980.
63. Hollinger FB and Dreesman GR. Hepatitis B virus antigens and albumin receptors. *Gastroenterology* 76:641-643, 1979.
64. Hollinger FB. Viral hepatitis. In: Kelley VC, ed. *Practice of Pediatrics, Vol. II*. Hagerstown, MD: Harper & Row, pp. 1-17, 1979.
65. Hollinger FB. Immunoprophylaxis for viral hepatitis-other views. *Gastroenterology* 77:187-189, 1979.
66. Ware AJ, Luby JP, Hollinger FB, Eigenbrodt EH, Cuthbert JA, Atkins CR, Shorey J, Hull AR and Combes B. Etiology of liver disease in renal-transplant patients. *Ann. Intern. Med.* 91:364-371, 1979.
67. Hollinger FB and Dreesman GR. Hepatitis Viruses. In: Rose NR and Friedman H, eds. *Manual of Clinical Immunology*, 2nd edition. Washington, D.C.: American Society for Microbiology, pp. 678-691, 1980.
68. Hollinger FB and Dienstag JL. Hepatitis Viruses. In: Lennette EH, ed. *Manual of Clinical Microbiology*, 3rd edition. Washington, D.C.: American Society for Microbiology, pp. 899-921, 1980.
69. Sanchez Y, Ionescu-Matiu I, Hollinger FB, Melnick JL and Dreesman GR. Antigenic relationship of a hepatitis B surface antigen-derived polypeptide and human serum albumin. *J. Gen. Virol.* 48:273-283, 1980.
70. Ionescu-Matiu I, Sanchez Y, Hollinger FB, Melnick JL and Dreesman GR. Presence of a receptor for albumin on individual HBsAg polypeptides and on HBsAg produced by a hepatoma cell line. *J. Med. Virol.* 6:175-178, 1980.
71. Katz D, Melnick JL and Hollinger FB. Characterization of HBeAg by physicochemical and immunochemical methods. *J. Med. Virol.* 5:87-100, 1980.

72. Hollinger FB, Mosley JW, Szmuness W, Aach RD, Peters RL and Stevens C. Transfusion-transmitted viruses study: experimental evidence for two non-A, non-B hepatitis agents. *J. Infect. Dis.* 142:400-407, 1980.
73. Hollinger FB and Graham DY. Diagnosing and treating rickettsial and parasitic hepatitis. *Drug Therapy* 10:95-109, 1980.
74. Sanchez Y, Ionescu-Matiu I, Dreesman GR, Kramp W, Six HR, Hollinger FB and Melnick JL. Humoral and cellular immunity to hepatitis B virus-derived antigens: comparative activity of Freund complete adjuvant, alum, and liposomes. *Infect. Immun.* 30:728-733, 1980.
75. Graham DY and Hollinger FB. When you suspect bacterial infection of the liver. *Drug Therapy* 10:89-94, 1980.
76. Skinhoj P, Hollinger FB, Hovind-Hougen K and Lous P. Infectious liver diseases in three groups of Copenhagen workers: correlation of hepatitis A infection to sewage exposure. *Arch. of Environ. Health* 36:139-143, 1981.
77. Dreesman GR, Hollinger FB, Sanchez Y, Oefinger P and Melnick JL. Immunization of chimpanzees with hepatitis B virus-derived polypeptides. *Infect. Immun.* 32:62-67, 1981.
78. Melnick JL, Dreesman GR and Hollinger FB. Characteristics of an experimental hepatitis B polypeptide vaccine. In: Maupas P and Guesry P, eds. *Hepatitis B Vaccine, INSERM Symposium 18*. Elsevier/North-Holland: Biomedical Press, pp. 239-249, 1981.
79. Aach RD, Szmuness W, Mosley JW, Hollinger FB, Kahn RA, Stevens CE, Edwards, VM and Werch J. Serum alanine aminotransferase of donors in relation to the risk of non-A, non-B hepatitis in recipients. *N. Engl. J. Med.* 304:989-994, 1981.
80. Hollinger FB, Alter HJ, Holland PV and Aach RD. Non-A, non-B posttransfusion hepatitis in the United States. In: Gerety RJ, ed. *Non-A, Non-B Hepatitis*. New York: Academic Press, pp. 49-70, 1981.
81. Hollinger FB. Immunoprophylaxis of health care personnel exposed to viral hepatitis. In: Keating LJ and Silvergleid AJ, eds. *Hepatitis A Technical Workshop*. Chicago: American Association of Blood Banks, pp. 127-147, 1981.
82. Sanchez Y, Ionescu-Matiu I, Dreesman GR, Hollinger FB and Melnick JL. Evidence for the presence of repeating antigenic determinants in the major and minor polypeptides derived from hepatitis B surface antigen. *Virology* 114:71-80, 1981.
83. Hollinger FB and Stevens CE. Viral hepatitis A, B, and non-A, non-B. In: Kelley VC, ed. *Practice of Pediatrics*. Philadelphia: Harper & Row, pp. 1-25, 1981.

84. Schulster LM, Hollinger FB, Dreesman GR and Melnick JL. Immunological and biophysical alteration of hepatitis B virus antigens by sodium hypochlorite disinfection. *Appl. Environ. Microbiol.* 42:762-767, 1981.
85. Hollinger FB and Heiberg D. Hepatitis B vaccine -- light at the end of the tunnel. *The Methodist Hospital Journal* 20:12-13, 1981.
86. Hollinger FB, Mosley JW, Szmunes W, Aach RD, Melnick JL, Afifi A, Stevens CE and Kahn RA. Non-A, non-B hepatitis following blood transfusion: Risk factors associated with donor characteristics. In: Szmunes W, Alter HJ and Maynard JE, eds. *Viral Hepatitis: 1981 International Symposium*. Philadelphia: Franklin Institute Press, pp. 361-376, 1982.
87. Hollinger FB, Adam E, Heiberg D and Melnick JL. Response to hepatitis B vaccine in a young adult population. In: Szmunes W, Alter HJ and Maynard JE, eds. *Viral Hepatitis: 1981 International Symposium*. Philadelphia: Franklin Institute Press, pp. 451-466, 1982.
88. Dreesman GR, Sanchez Y, Ionescu-Matiu I, Sparrow JT, Six HR, Peterson DL, Hollinger FB and Melnick JL. Antibody to hepatitis B surface antigen after a single inoculation of uncoupled synthetic HBsAg peptides. *Nature* 295:158-160, 1982.
89. Melnick JL, Dreesman GR and Hollinger FB. Hepatitis B vaccines: expectations and realities for the prevention of infection and of primary hepatocellular carcinoma. *Infect. Dis.* 12:No. 8, 1982.
90. Melnick JL, Dreesman GR, Hollinger FB, Sanchez Y, Ionescu-Matiu I and Sparrow JT. Synthetic peptide vaccine for hepatitis B. *Proceedings of the 1st International Conference on the Impact of Viral Diseases on the Development of Latin American Countries and the Caribbean Region (Rio de Janeiro, Brasil)*, Vol. 1, pp. 344-353, 1982.
91. Chin TW, Hollinger FB, Rich RR, Troisi CL, Dreesman GR and Melnick JL. Cytotoxicity by NK-like cells from hepatitis B-immune patients to a human hepatoma cell line secreting HBsAg. *J. Immunol.* 130:173-180, 1983.
92. Kennedy RC, Dreesman GR, Sparrow JT, Culwell AR, Sanchez Y, Ionescu-Matiu I, Hollinger FB and Melnick JL. Inhibition of a common human anti-hepatitis B surface antigen idiotype by a cyclic synthetic peptide. *J. Virol.* 46:653-655, 1983.
93. Hollinger FB, Khan NC, Oefinger PE, Yawn DH, Schmulen AC, Dreesman GR and Melnick JL. Posttransfusion hepatitis type A. *JAMA* 250:2313-2317, 1983.

94. Adler-Storthz K, Schulster LM, Dreesman GR, Hollinger FB and Melnick JL. Effect of alkaline gluteraldehyde on hepatitis B virus antigens. *Eur. J. Clin. Microbiol.* 2:316-320, 1983.
95. Hollinger FB, Dreesman GR, Sparrow J and Melnick JL. Synthetic peptide vaccine for hepatitis B. *Develop. Biol. Standard.* 54:113-116, 1983.
96. Hollinger FB, Dreesman GR and Melnick JL. Synthetic peptide vaccine for hepatitis B. In: Overby LR, Deinhardt F and Deinhardt J, eds. *Viral Hepatitis Second International Max von Pettenkofer Symposium.* New York: Marcel Dekker, pp. 303-305, 1983.
97. Khan NC, Hollinger FB and Melnick JL. Localization of hepatitis A virus antigen to specific subcellular fractions of hepatitis-A-infected chimpanzee liver cells. *Intervirology* 21:187-194, 1984.
98. Asaka M, Miyazaki T, Hollinger FB and Alpert E. Human aldolase B serum levels: a marker of liver injury. *Hepatology* 4:531-535, 1984.
99. Hollinger FB, Dolana G, Thomas W and Gyorkey F. Reduction in risk of hepatitis transmission by heat-treatment of a human factor VIII concentrate. *J. Infect. Dis.* 150:250-262, 1984.
100. Hollinger FB. Prevention of posttransfusion hepatitis. In: Vyas GN, Dienstag JL and Hoofnagle JH, eds. *Viral Hepatitis and Liver Disease.* Orlando: Grune and Stratton, pp. 319-337, 1984.
101. Melnick JL, Dreesman GR, Hollinger FB, Sparrow JT, Kennedy RC, Sanchez Y and Ionescu-Matiu I. Synthetic peptide hepatitis B vaccine. In: *Table Ronde Roussel Uclaf, No. 48: Synthetic Vaccines, Institut Scientifique Roussel, Paris,* pp. 29-30, 1984.
102. Stevens CE, Aach RD, Hollinger FB, Mosley JW, Szmunes W, Kahn R, Werch J and Edwards V. Hepatitis B virus antibody in blood donors and the occurrence of non-A, non-B hepatitis in transfusion recipients. An analysis of the Transfusion-Transmitted Viruses Study. *Ann. Intern. Med.* 101:733-738, 1984.
103. Hollinger FB and Dienstag JL. Hepatitis viruses. In: Lennette EH, Balows A, Hausler JR and Shadomy HJ, eds. *Manual of Clinical Microbiology, 4th edition.* Washington, D.C.: American Society for Microbiology, pp. 813- 835, 1985.
104. Hollinger FB, Melnick JL and Robinson WS, eds. *Viral Hepatitis: Biological and Clinical Features, Specific Diagnosis, and Prophylaxis.* New York: Raven Press, 1985.
105. Hollinger FB and Melnick JL. Viral Hepatitis. In: Lennette EH, ed. *Laboratory Diagnosis of Viral Infections.* New York: Marcel Dekker, Inc., pp. 293-311, 1985.

106. Troisi CL and Hollinger FB. Detection of an IgM antiidiotype directed against anti-HBs in hepatitis B patients. *Hepatology* 5:758-762, 1985.
107. Troisi CL, Heiberg DA and Hollinger FB. Normal immune response to hepatitis B vaccine in patients with Down's Syndrome. A basis for immunization guidelines. *JAMA* 254:3196-3199, 1985.
108. Zahradnik JM, Heiberg D and Hollinger FB. Hepatitis B vaccine: immune responses in children from families with an HBsAg carrier. *Vaccine* 3:407-413, 1985.
109. Hollinger FB and Dreesman GR. Immunobiology of hepatitis viruses. In: Rose NR, Friedman H and Fahey JL, eds. *Manual of Clinical Laboratory Immunology*, 3rd edition. Washington, D.C.: American Society for Microbiology, pp. 558-572, 1986.
110. Hollinger FB. Jaundice and liver infections. In: Pickering LK and DuPont HL, eds. *Infectious Diseases of Children and Adults*. Menlo Park: Addison-Wesley Publication Company, pp. 403-443, 1986.
111. Yoffe B, Noonan CA, Melnick JL and Hollinger FB. Hepatitis B virus DNA in mononuclear cells and analysis of cell subsets for the presence of replicative intermediates of viral DNA. *J. Infect. Dis.* 153:471-477, 1986.
112. Hollinger FB, Troisi CL and Pepe PE. Anti-HBs responses to vaccination with a human hepatitis B vaccine made by recombinant DNA technology in yeast. *J. Infect. Dis.* 153:156-159, 1986.
113. Khan NC and Hollinger FB. Non-A, non-B hepatitis agent. *Lancet* 1:41, 1986.
114. Pepe PE, Hollinger FB, Troisi CL and Heiberg D. Viral hepatitis risk in urban emergency medical services personnel. *Ann. Emerg. Med.* 15:454-457, 1986.
115. Hollinger FB, Troisi CL, Heiberg D, Sanchez Y, Dreesman, GR and Melnick JL. Response to a hepatitis B polypeptide vaccine in micelle form in a young adult population. *J. Med. Virol.* 19:229-240, 1986.
116. Noonan CA, Yoffe B, Mansell PWA, Melnick JL and Hollinger FB. Extrachromosomal sequences of hepatitis B virus DNA in peripheral blood mononuclear cells of acquired immune deficiency syndrome patients. *Proc. Natl. Acad. Sci. USA* 83:5698-5702, 1986.
117. Hollinger FB. Hepatitis markers: Guide to test selection. *Diagnosis* 8:52-69, 1986.
118. Yoffe B, Lewis DE, Petrie BL, Noonan CA, Melnick JL and Hollinger FB. Fusion as a mediator of cytolysis in mixtures of uninfected CD4⁺ lymphocytes and cells infected by human immunodeficiency virus. *Proc. Natl. Acad. Sci. USA* 84:1429-1433, 1987.

119. Hollinger FB. Serologic evaluation of viral hepatitis. *Hosp. Prac.* 22:101-114, 1987.
120. Kerman RH, Flechner SM, Van Buren CT, Lorber MI, Dawson G, Falk L, Gutierrez R, Hollinger FB and Kahan BD. Investigation of HTLV-3 serology in a renal transplant population. *Transplantation* 43:244-248, 1987.
121. Hollinger FB. Hepatitis B vaccines -- to switch or not to switch. *JAMA* 257:2634-2636, 1987.
122. Hollinger FB. Experimental models of chronic hepatitis B and their potential role in developing therapeutic strategies. In: American Association for the Study of Liver Diseases, Postgraduate Course, October 25-26, "Advances in hepatobiliary diseases seen in practice", pp. 270-286, 1987.
123. Hollinger FB. Specific and surrogate screening tests for hepatitis. In: Insalaco SJ and Menitove JE, eds. *Transfusion-Transmitted Viruses: Epidemiology and Pathology*. Arlington, VA: American Association of Blood Banks, pp. 69-86, 1987.
124. Lewis DE, Yoffe B, Bosworth CG, Hollinger FB and Rich RR. Cellular pathogenesis induced by human immunodeficiency virus. III International Conference on AIDS, 1987.
125. Troisi CL and Hollinger FB. Current tests for antibody to hepatitis B core antigen used to screen donors for non-A, non-B hepatitis are comparable to the original radioimmunoassay for hepatitis B core antigen. *Transfusion* 27:438-440, 1987.
126. Melnick JL, Gyorkey F, Noonan CA, Yoffe B, Lewis DE, Petrie BL and Hollinger FB. HBV and HIV. In: Villarejos VM, ed. *Viral Hepatitis and AIDS (Proceedings of the International Symposium Viral Hepatitis and AIDS, San Jose, Costa Rica)*. Louisiana State University - International Training Center for Medical Research and Training, pp. 111-124, 1987.
127. Hollinger FB. Die diagnostik der virushepatitis. *Diagnose and Labor* 37:137-156, 1987.
128. Garcia G and Hollinger FB. Hepatitis B virus infection and renal transplantation. *Hepatology* 8:1172-1174, 1988.
129. Lewis DE, Yoffe B, Bosworth CG, Hollinger FB and Rich RR. Human immunodeficiency virus-induced pathology favored by cellular transmission and activation. *FASEB-J* 2:251-255, 1988.
130. Szucs G, Melnick JL and Hollinger FB. A simple assay based on HIV infection preventing the reclustering of MT-4 cells. *Bull WHO* 66:729-737, 1988.

131. Hollinger FB. Factors influencing the response to hepatitis B vaccine. In: Hepatitis Scientific Memoranda (HSM) Symposium: Immunization against Hepatitis B, February 26, 1988, Ising, W. Germany, p. 48, 1988.
132. Hollinger FB. Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations. *Am. J. Med.* 87(3A):36S-40S, 1989.
133. Brewton GW, Hersh EM, Rios A, Mansell PWA, Hollinger FB and Reuben JM. A pilot study of diethyldithiocarbamate in patients with acquired immune deficiency syndrome (AIDS) and the AIDS-related complex. *Life Sciences* 45:2509-2520, 1989.
134. Clarke JA, Hollinger FB, Lewis E, Russell LA, Miller CH, Huntley A and Flynn NM. Intradermal inoculation with Heptavax-B. Immune response and histologic valuation of injection sites. *JAMA* 262:2567-2571, 1989.
135. Dimitrov DH, Shindarov LM, Melnick JL and Hollinger FB. AIDS in Bulgaria. *Nature [letter]* 341:275, 1989.
136. Yoffe B, Petrie BL, Noonan CA and Hollinger FB. In vivo and in vitro ultrastructural alterations induced by human immunodeficiency virus in human lymphoid cells. *Lab. Invest.* 61:303-309, 1989.
137. Dimitrov DH, Melnick JL and Hollinger FB. Microculture assay for isolation of human immunodeficiency virus type 1 and for titration of infected peripheral blood mononuclear cells. *J. Clin. Microbiol.* 28:734-737, 1990.
138. Hollinger FB. Hepatitis B virus. In: Fields BN, Knipe DM, Chanock RM, Hirsch MS, Melnick JL, Monath TP and Roizman B, eds. *Fields Virology*, 2nd edition. New York: Raven Press, pp. 2171-2236, 1990.
139. Hollinger FB and Ticehurst J. Hepatitis A virus. In: Fields BN Knipe, DM, Chanock RM, Hirsch MS, Melnick JL, Monath TP and Roizman B, eds. *Fields Virology*. New York: Raven Press, pp. 631-667, 1990.
140. Hollinger FB. Non-A, non-B hepatitis viruses. In: Fields BN, Knipe DM, Chanock, RM, Hirsch MS, Melnick JL, Monath TP and Roizman B, eds. *Fields Virology*. New York: Raven Press, pp. 2239-2273, 1990.
141. Mosley JW, Aach RD, Hollinger FB, Stevens CE, Barbosa LH, Nemo GJ, Holland PV, Bancroft WH, Zimmerman HJ, Kuo G, Choo Q-L and Houghton M. Non-A, non-B hepatitis and antibody to hepatitis C virus. *JAMA* 263:77-78, 1990.

142. Hollinger FB and Glombicki AP: Hepatitis A Virus. In: Mandell GL, Douglas RG, and Bennett JE, eds. Principles and Practice of Infectious Diseases, 3rd edition. New York: Churchill Livingstone, pp. 1383-1399, 1990.
143. Roberts RB, Hollinger FB, Parks WP, Rasheed S, Laurence J, Heseltine PNR, Makuch RW, Lubina JA, Johnson KM and the Ribavirin-LAS Collaborative Group. A multicenter clinical trial of oral ribavirin in HIV-infected people with lymphadenopathy: virologic observations. AIDS 4:67-72, 1990.
144. Hollinger FB and the North American Regional Study Group. Controlling hepatitis B virus transmission in North America. Proceedings of the International Conference on Prospects for Eradication of Hepatitis B Virus, Geneva, Switzerland, February 1989. Vaccine 8:122-128 [Suppl.], 1990.
145. Troisi CL and Hollinger FB. Hepatitis B vaccines. In: Popper H and Schaffner F, eds. Progress in Liver Diseases, Vol. 9. Philadelphia: W. B. Saunders Company, pp. 405-442, 1990.
146. Dimitrov DH, Shindarov LM, Melnick JL, Bremer J, Dimitrova DA, Beshkov DA and Hollinger FB. Isolation of HIV-1 and demonstration of HIV-1 proviral sequences in seropositive individuals from Bulgaria. Compt. Rend. Acad. Bulg. Sci. 43:129-131, 1990.
147. Bremer JW and Hollinger FB. Pediatric HIV infection and AIDS: diagnostic tests. Sem. Ped. Infect. Dis. 1:27-30, 1990.
148. Hollinger FB. Factors influencing the immune response to hepatitis B vaccine and duration of immunity. In: HepatoCite: International Hepatitis Update 3:1-5, ADIS International Limited, 1990.
149. Hollinger FB. Hepatitis B vaccines and factors influencing immunity. In: Sung J-L and Chen DS, eds. Viral hepatitis and hepatocellular carcinoma. Proceedings of the Second International Symposium on Viral Hepatitis and Hepatocellular Carcinoma. Hong Kong: Excerpta Medica Asia Ltd., pp. 385-386, 1990.
150. Dimitrov DH, Melnick JL and Hollinger FB. Isolation of HIV-1 and titration of infected peripheral blood mononuclear cells by microculture. In: Khan NC and Melnick JL, eds. Human Immunodeficiency Virus: Innovative Techniques for Isolation and Identification, Monographs in Virology. Basel: S. Karger 18:122-130, 1990.
151. Hollinger FB and Ticehurst J. Hepatitis A Virus. In: Hollinger FB, Robinson WS, Purcell RH, Gerin JL and Ticehurst J, eds. Viral Hepatitis, 2nd edition. New York: Raven Press, pp. 1-37, 1991.

152. Hollinger FB. Hepatitis B Virus. In: Hollinger FB, Robinson WS, Purcell RH, Gerin JL and Ticehurst J, eds. *Viral Hepatitis*, 2nd edition. New York: Raven Press, pp. 73-138, 1991.
153. Hollinger FB. Non-A, Non-B Hepatitis Viruses. In: Hollinger FB, Robinson WS, Purcell RH, Gerin JL and Ticehurst J, eds. *Viral Hepatitis*, 2nd edition. New York: Raven Press, pp. 139-173, 1991.
154. Hollinger FB. Hepatitis B Virus: The disease and its sequelae. In: Douglas RG and Hilleman M, eds. *Assessment and Management of Risks Associated with Hepatitis: effectiveness of intervention*. Philadelphia: Hanley and Beifus, Inc., 1991.
155. Hollinger FB. Antibodies and antigens furnish many answers. *Consultant* 31:33-42, 1991.
156. Hollinger FB, Lemon SM and Margolis HS, eds. *Viral Hepatitis and Liver Disease*. Baltimore: Williams and Wilkins 1991.
157. Qavi HB, Green MT, SeGall GK, Hollinger FB and Lewis DE. The incidence of HIV-1 and HHV-6 in corneal buttons. *Curr. Eye Res.* 10: [Suppl.] 97-103, 1991.
158. Hollinger FB and Dreesman GR. Hepatitis Viruses. In: Rose NR, de Macario EC, Fahey JL, Friedman H and Penn GM, eds. *Manual of Clinical Laboratory Immunology*, 4th edition. Washington, D.C.: American Society for Microbiology, pp. 634-650, 1991.
159. Hollinger FB, Dienstag JL and Swenson PD. Hepatitis Viruses*. In: *Manual of Clinical Microbiology*, 5th edition. Washington, D.C.: American Society for Microbiology, pp. 959-983, 1991.
160. Noonan CA, Schmaltz KM, Moore WT, Shingu M, Yoffee B and Hollinger FB. Cloning and expression of the hepatitis B virus DNA polymerase gene in a recombinant baculovirus system. In: Hollinger FB, Lemon SM and Margolis HS, eds. *Viral Hepatitis and Liver Disease*. Baltimore: Williams and Wilkins, pp. 189-195, 1991.
161. Hollinger FB. Tribute to Joseph L. Melnick, Ph.D., D.Sc. In: Hollinger FB, Lemon SM and Margolis HS, eds. *Viral Hepatitis and Liver Disease*. Baltimore: Williams and Wilkins, pp. 3-4, 1991.
162. Mosley JW, Stevens CE, Aach RD, Hollinger FB and Barbosa LH. Role of hepatitis C virus infection in transfusion-associated non-A, non-B hepatitis. In: Hollinger FB, Lemon SM and Margolis HS, eds. *Viral Hepatitis and Liver Disease*. Baltimore: Williams & Wilkins, pp. 402-407, 1991.

163. Troisi CL, Hollinger FB, Hoots WK, et al. Delta virus infection and liver disease in hemophilic patients. In: Hollinger FB, Lemon SM and Margolis HS, eds. *Viral Hepatitis and Liver Disease*. Baltimore: Williams & Wilkins, pp. 487-491, 1991.
164. Aach RD, Stevens CE, Hollinger FB, et al. Hepatitis C virus infection in post-transfusion hepatitis: an analysis with first- and second-generation assays. *N. Engl. J. Med.* 325:1325-1329, 1991.
165. Hollinger FB, Bremer JW, Myers LE, Gold JWM, McQuay L and the NIH/NIAID/DAIDS/ACTG Virology Laboratories. Standardization of sensitive HIV coculture procedures and establishment of a multicenter quality assurance program for the AIDS clinical trials group (ACTG). *J. Clin. Microbiol.* 30:1787-1794, 1992.
166. Han KH, Hollinger FB, Noonan CA and Yoffe B. Simultaneous detection of HBV-specific antigens and DNA in paraffin-embedded liver tissue by immunohistochemistry and in situ hybridization. *J. Virol. Methods.* 37:89-98, 1992.
167. Hollinger FB and Lin HJ. Community-acquired hepatitis C virus infection (Editorial) *Gastroenterology* 102:1426-1429, 1992.
168. Gwaltney JM Jr, Hendley O, Hayden FG, McIntosh K, Hollinger FB, Melnick JL and Turner RB. Updated recommendations for safety-testing of viral inocula used in volunteer experiments on rhinovirus colds. *Prog. Med. Virol.* 39:256-263, 1992.
169. Qavi HB, Green MT, Segall GK, Lewis DE and Hollinger FB. Frequency of dual infections of corneas with HIV-1 and HHV-6. *Curr. Eye Res.* 11:315-323, 1992.
170. Qavi HB, Green MT, SeGall GK, Lewis DE and Hollinger FB. Transcriptional activity of HIV-1 and HHV-6 in retinal lesions from AIDS patients. *Invest. Ophthal. Vis. Sci.* 33:2759-2767, 1992.
171. Lin HJ, Shi N, Mizokami M and Hollinger FB. Polymerase chain reaction assay for hepatitis C virus RNA using a single tube for reverse transcription and serial rounds of amplification with nested primer pairs. *J. Med. Virol.* 38:220-225, 1992.
172. Seeff LB, Buskell-Bales ZB, Wright EC, Durako SJ, Alter HJ, Iber FL, Hollinger FB, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. *N. Engl. J. Med.* 327:1906-1911, 1992.
173. Mathur S, Verseman S, Estrada R and Hollinger FB. Bleeding from a Meckel's diverticulum after the use of ibuprofen. *Am. J. Gastroenterol.* 87:1992.
174. Hollinger FB, Andre FE, Melnick J, eds. International symposium on active immunization against hepatitis A. *Vaccine*, 10:Suppl 1; S6-S7, 1992.

175. Dimitrov DH, Hollinger FB, Baker CJ, Kline MW, Doyle M, Bremer JW and Shearer WT. Study of human immunodeficiency virus resistance to 2'-3'-dideoxyinosine and zidovudine in sequential isolates from pediatric patients on long-term therapy. *J. Infect. Dis.* 167:818-823, 1993.
176. Troisi CL, Hollinger FB, Hoots WK, et al. A multicenter study of viral hepatitis in a United States hemophilic population. *Blood* 81:412-418, 1993.
177. Mimms LT, Mosley JW, Hollinger FB, Stevens CE, Aach RD, Cunningham M, et al. Effect of concurrent acute infection with hepatitis C virus on acute hepatitis B virus infection. *BMJ* 307:1095-1097, 1993.
178. Kline MW, Hollinger FB, Rosenblatt HM, Bohannon B, Kozinetz CA and Shearer WT. Sensitivity, specificity and predictive value of physical examination, culture and other laboratory studies in the diagnosis during early infancy of vertically acquired human immunodeficiency virus infection. *Pediatr. Infect. Dis. J.* 12:33-36, 1993.
179. Jackson JB, Drew J, Lin HJ, Otto P, Bremer J, Hollinger FB, et al. Establishment of a quality assurance program for human immunodeficiency virus type 1 DNA polymerase chain reaction assays by the AIDS clinical trials group. *J. Clin. Microbiol.* 31:3123-3128, 1993.
180. Lin HJ, Lau JYN, Lauder IJ, Shi N, Lai C and Hollinger FB. The hepatitis C virus genome: a guide to its conserved sequences and candidate epitopes. *Virus Research* 30:27-41, 1993.
181. Han KH, Hollinger FB, Noonan CA, Solomon H, Klintmalm GBG, Genta RM and Yoffe B. Southern-blot analysis and simultaneous *in situ* detection of hepatitis B virus-associated DNA and antigens in patients with end-stage liver disease. *Hepatology* 18:1032-1038, 1993.
182. Douglas DD, Rakela J, Lin HJ, Hollinger FB, et al. Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C: comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM. *Dig. Dis. Sci.* 38:601-607, 1993.
183. De Gruttola V, Beckett LA, Coombs RW, Arduno JM, Balfour HH, Jr., Rasheed S, Hollinger FB, et al. Serum p24 antigen levels as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1. *J. Infect. Dis.* 69:713-721, 1994.
184. Myers LE, Hollinger FB and McQuay LJ. Dilution Assay Statistics. *J. Clin Microbiol.* 32:732-739, 1994.

185. Kline MW, Lewis DE, Hollinger FB, et al. A comparative study of human immunodeficiency virus (HIV) culture, polymerase chain reaction and anti-HIV immunoglobulin A antibody detection in the diagnosis during early infancy of vertically acquired HIV infection. *Pediatr. Infect. Dis. J.* 13:90-94, 1994.
186. Kuwada SK, Patel VM, Hollinger FB, Lin HJ, Yarbough PO, Wiesner RH, Kaese D and Rakela J. Non-A, non-B fulminant hepatitis is also non-E and non-C. *Am. J. Gastroenterol.* 89:57-61, 1994.
187. Lin HJ, Myers LE, Yen-Lieberman B, Hollinger FB, et al. Multicenter evaluation of quantification methods for plasma human immunodeficiency virus type 1 RNA. *J. Infect. Dis.* 170:553-562, 1994.
188. Mosley JW, Stevens CE, Aach RD, Hollinger FB, et al. Donor screening for antibody to hepatitis B core antigen and hepatitis B virus infection in transfusion recipients. *Transfusion* 35:5-12, 1995.
189. Hollinger FB, Mouneimne Y, Lahart C, Tosi PF, Dimitrov D and Nicolau C. Life span of circulating membrane CD4 inserted into the plasma membranes of autologous red blood cells of HIV-infected subjects. *J. AIDS Hum. Retrovirol.* 9:126-132, 1995.
190. Lewis DE, Adu-Oppong A, Hollinger FB, et al. Sensitivity of immune complex-dissociated p24 antigen testing for early detection of human immunodeficiency virus in infants. *Clin. Diagn. Lab. Immunol.* 2:87-90, 1995.
191. Hollinger FB. (Guest Editor - An overview of the clinical development of hepatitis A vaccine). Introduction. *J. Infect. Dis.* 171 (Suppl 1):S1, 1995.
192. Hollinger FB, Eickhoff T, Gershon A, Jong EC and Koff RS. Discussion: who should receive hepatitis A vaccine? A strategy for controlling hepatitis A in the United States. *J. Infect. Dis.* 171 (Suppl 1): S73-S77, 1995.
193. Lin HJ, Siwak EB, Lauder IJ and Hollinger FB. Single-strand conformation polymorphism study of human immunodeficiency virus type 1 RNA and DNA in plasma, peripheral blood mononuclear cells and their virologic cultures. *J. Infect. Dis.* 171:1619-1622, 1995.
194. Qavi HB, Green MT, Lewis DE, Hollinger FB, Pearson G and Ablashi DV. HIV-1 and HHV-6 antigens and transcripts in retinas of patients with AIDS in the absence of human cytomegalovirus. *Invest. Ophthalmol. Vis. Sci.* 36:2040-2047, 1995.
195. Kozinetz CA, Kline MW, Lewis DE, Hollinger FB, et al. Early detection of HIV in infants - aspects of design and analysis for diagnostic test studies. *Ped. AIDS HIV Infect-Fetus to Adolesc.* 6:3-13, 1995.

196. Hollinger FB and Dienstag JL. Hepatitis B and D Viruses. In: Manual of Clinical Microbiology, 6th edition. Washington, D.C.: American Society for Microbiology. 1995.
197. Hollinger FB. Extrahepatic manifestations associated with chronic hepatitis C. *Turk. J. Gastroenterol.* 6:314-316, 1995.
198. Hollinger FB and Ticehurst JR. Hepatitis A virus. In: Fields BN, Knipe DM, Howley PM, et al. (eds). *Fields Virology*, 3rd edition. Philadelphia: Lippincott-Raven Publishers; pp. 735-782, 1996.
199. Hollinger FB. Hepatitis B virus. In: Fields BN, Knipe DM, Howley PM, et al. (eds). *Fields Virology*, 3rd edition. Philadelphia: Lippincott-Raven Publishers; pp. 2739-2807, 1996.
200. Lauder IJ, Lin HJ, Siwak EB and Hollinger FB. Kernel density analysis of variable and conserved regions of the envelope proteins of human immunodeficiency virus type 1 and associated epitopes. *AIDS Res. Hum. Retrovir.* 12:91-97, 1996.
201. Lin HJ, Haywood M and Hollinger FB. Application of a commercial kit for detection of PCR products to quantification of human immunodeficiency virus type 1 RNA and proviral DNA. *J. Clin. Microbiol.* 34:329-333, 1996.
202. Hollinger FB. Comprehensive control (or elimination) of HBV transmission in the United States. *GUT (Suppl 2)*: S24-S30, 1996.
203. Scott WA, Brambilla D, Siwak EB, Beatty C, Bremer J, Coombs RW, Farzadegan H, Fiscus SA, Hammer SM, Hollinger FB, et al. Evaluation of an infectivity standard for real-time quality control of human immunodeficiency virus type 1 quantitative micrococulture assays. Participating Laboratories of the AIDS Clinical Trials Group. *J. Clin. Microbiol.* 34:2312-2315, 1996.
204. Mosley JW, Huang W, Stram DO, Nowicki MJ, Hollinger FB, Aach RD, Stevens CE, et al. Donor levels of serum alanine aminotransferase activity and antibody to hepatitis B core antigen associated with recipient hepatitis C and non-B, non-C outcomes. *Transfusion* 36:776-781, 1996.
205. Troisi C, Hollinger FB, and the Delta Hepatitis Study Group. Interactions between hepatitis C and HIV in hemophiliacs: results of a 7 year follow-up study. Proceedings of the IX Triennial International Symposium on Viral Hepatitis and Liver Disease, Rome, Italy, April 21-25, 1996. In: Rizzetto M, Purcell RH, Gerin JL, and Verme G, eds. *Viral Hepatitis and Liver Disease*. Turin: Edizioni Minerva Medica, pp. 258-260, 1997.

206. Mosley JW, Kim JP, Dawson GF, Aach RD, Hollinger FB, Stevens CD, Barbosa CH, Nemo GJ, and Nowicki MJ. HGV/GBV-C detection among patients in the transfusion-transmitted viruses study. Proceedings of the IX Triennial International Symposium on Viral Hepatitis and Liver Disease, Rome, Italy, April 21-25, 1996. In: Rizzetto M, Purcell RH, Gerin JL, and Verme G, eds. *Viral Hepatitis and Liver Disease*. Turin: Edizioni Minerva Medica, pp. 368-371, 1997.
207. Dille BJ, Gutierrez RA, Surowy TK, Coleman PF, Knigge MF, Carrick RJ, Aach RD, Stevens CE, Hollinger FB, et al. An ELISA for detection of antibodies to the E2 protein of GB virus C. *J. Infect. Dis.* 175:458-461, 1997.
208. Kalish LA, Pitt J, Lew J, Landesman S, Diaz C, Hershow R, Hollinger FB, et al. Defining the time of fetal or perinatal acquisition of human immunodeficiency virus type 1 infection on the basis of age at first positive culture. *J. Infect. Dis.* 175:712-715, 1997.
209. Lin HJ, Tanwandee T and Hollinger FB. Improved methods for quantification of human immunodeficiency virus type 1 (HIV-1) RNA and hepatitis C virus (HCV) RNA in blood using spin column technology and chemiluminescent assays of PCR products. *J. Med. Virol.* 51:56-63, 1997.
210. Anand BS and Hollinger FB. Prevention of hepatocellular carcinoma with vaccines. In: Okuda K and Tabor E, eds. *Liver Cancer*. New York: Churchill Livingstone Publishers; pp. 415-424, 1997.
211. Hollinger FB and Dreesman GR. Hepatitis Viruses. In *Manual of Clinical Laboratory Immunology*, 5th edition. Washington, D.C.: American Society for Microbiology; pp. 702-718, 1997.
212. Troisi C, Hollinger FB, Krause DS and Pickering LK. Immunization of seronegative infants with hepatitis A vaccine (HAVRIX®; SKB): A comparative study of two dosing schedules. *Vaccine* 15:1613-1617, 1997.
213. Tong MJ, Reddy KR, Lee WM, Pockros PJ, Hoefs JC, Keeffe EB, Hollinger FB, et al. Treatment of chronic hepatitis C with consensus interferon: A multicenter, randomized, controlled trial. *Hepatology* 26:747-754, 1997.
214. Keeffe EB, Hollinger FB and the CIFN Study Group. Therapy of chronic hepatitis C: Consensus interferon trials. *Hepatology* 26(Suppl):101S-107S, 1997.
215. Troisi C and Hollinger FB. Detection of antibodies to hepatitis C virus in seronegative patients using an immune complex dissociation assay. *J. Viral Hepatitis* 4:383-386, 1997.

216. Lin HJ, Pedneault L and Hollinger FB. Intra-assay performance characteristics of five assays for quantification of human immunodeficiency virus type 1 RNA in plasma. *J. Clin. Microbiol.* 36:835-839, 1998.
217. Heathcote EJJ, Keeffe EB, Lee SS, Feinman SV, Tong MJ, Reddy KR, Albert DG, Witt K, Blatt LM, and the CIFN Study Group. Re-treatment of chronic hepatitis C with consensus interferon. *Hepatology* 27:1136-1143, 1998.
218. Pockros PJ, Tong M, Lee WM, van Leeuwen DJ, et al. Relationship between biochemical and virological responses to interferon therapy in chronic hepatitis C infection. *J. Viral Hepatitis* 5:271-276, 1998.
219. Thomas DL, Villano SA, Riester KA, et al. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. *J. Infect. Dis.* 177:1480-1488, 1998.
220. Lin HJ, Siwak EB, Lauder IJ and Hollinger FB. Selection of appropriate HIV-1 genomic regions for single-strand confirmation polymorphism (SSCP) analysis of the diversity, modification and transmission of HIV-1 quasispecies. *J. AIDS Res. Hum. Retrovir.* 18:409-416, 1998.
221. Lee WM, Reddy KR, Tong M, Black M, Van Leeuwen DJ, Hollinger FB, et al. Early HCV RNA responses predict interferon treatment outcomes in chronic hepatitis C. *Hepatology* 28:1411-1415, 1998.
222. Hollinger FB, Purcell RH, Lavanchy D, and a WHO Consultation Panel of International Experts. Global surveillance and control of hepatitis C: Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. *J. Viral Hepatitis.* 6:35-47, 1999.
223. Bonkovsky HL, Woolley JM, and the Consensus Interferon Study Group. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. *Hepatology* 29:264-270, 1999.
224. Pockros PJ, Bain VG, Hunter EB, Conrad A, Balart A, Hollinger FB, Albert D and the Consensus Interferon Study Group. A comparison of reverse transcription-polymerase chain reaction (RT-PCR) and branched-chain DNA (bDNA) assays for hepatitis C virus RNA in patients receiving interferon treatment. *J. Viral Hepatitis.* 6:145-150, 1999.
225. Hollinger FB and Dienstag JL. Hepatitis B and D Viruses. In: *Manual of Clinical Microbiology*, 7th edition. Washington, D.C.: American Society for Microbiology; pp. 1025-1042, 1999.

226. Heathcote EJ, James S, Mullen KD, Hauser SC, et al. Chronic hepatitis C virus patients with breakthroughs during interferon treatment can successfully be treated with consensus interferon. *Hepatology* 30:562-566, 1999.
227. Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. *Hepatology* 30:787-793, 1999.
228. Keeffe EB, Dusheiko GM, James SP, Mullen KD, et al. Utility of hepatitis C virus genotypes in predicting response to treatment of chronic hepatitis C. *Cytokines Cell Mol. Ther.* 5:207-210, 1999.
229. Keeffe EB, Dusheiko GM, Tong MJ, Hollinger FB, et al. Genotype does not affect pattern of HCV RNA decrease among responders during interferon treatment of chronic hepatitis C. *Cytokines Cell Mol. Ther.* 5:211-216, 1999.
230. Hollinger FB. Factors contributing to the evolution and outcome of cirrhosis in hepatitis C. In: *Clinics in Liver Disease, Treatment of Chronic Hepatitis C*. Philadelphia: W.B. Saunders Company Publishers; pp. 741-755, 1999.
231. Jensen DM, Krawitt EL, Keeffe EB, Hollinger FB, et al. Biochemical and viral response to consensus interferon (CIFN) therapy in chronic hepatitis C patients: Effect of baseline viral concentration. *Am. J. Gastroenterol.* 94:3583-3588, 1999.
232. Hollinger FB. Progress towards the comprehensive control of HBV. *Gastroenterology and Hepatology.* 15(Suppl):123-124, 2000.
233. Harris DR, Gonin Rene, Alter HJ, Wright EC, Buskell ZJ, Hollinger FB, et al. The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. *Ann. Int. Med.* 134:120-124, 2001.
234. Seeff LB, Hollinger FB, Alter HJ, et al. Long-term mortality and morbidity of transfusion-associated Non-A, Non-B and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. *Hepatology* 33:455-463, 2001.
235. Lin HJ, Siwak EB, Lauder IJ and Hollinger FB. Long-term culture of human immunodeficiency virus type 1 resulting in loss of glycosylation sites. *J Med. Virol.* 63:197-202, 2001.
236. Bonacini M, Lin HJ, and Hollinger FB. Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus. *J. Acquir. Immune Defic. Syndr.* 26:340-344, 2001.
237. Hollinger FB and Emerson SU. Hepatitis A virus. In: Knipe DM, Howley PM, Griffin DE, et al. (eds). *Fields Virology*, 4th edition. Philadelphia: Lippincott Williams & Wilkins Publishers; pp. 799-840, 2001.

238. Hollinger FB and Liang TJ. Hepatitis B virus. In: Knipe DM, Howley PM, Griffin DE, et al. (eds). *Fields Virology*, 4th edition. Philadelphia: Lippincott Williams & Wilkins Publishers; pp. 2971-3036, 2001.
239. Lin HJ, Seeff LB, Barbosa L and Hollinger FB. Occurrence of identical hypervariable region 1 sequences of hepatitis C virus in transfusion recipients and their respective blood donors: divergence over time. *Hepatology* 34:424-9, 2001.
240. LaRussa P, Magder L, Pitt J, Sill A, Kufera J, Hillyer G, Hollinger B, et al. Association of HIV-1 Viral Phenotype in the MT-2 Assay with Perinatal HIV Transmission. *J. Acquir. Immune Defic. Syndr.* 30:88-94, 2002.
241. Nurgalieva ZZ, Malaty HM, Graham DY, et al. Helicobacter Pylori Infection in Kazakhstan: Effect of Water Source and Household Hygiene. *Am. J. Trop. Med. Hyg.* 67(2):201-206, 2002.
242. Hollinger FB, Kirtava A, Oakley M, et al. Blood Safety Monitoring Among Persons with Bleeding Disorders --- United States, May 1998—June 2002. *Morbidity and Mortality Weekly Report MMWR* 51:1152-1154, 2003.
243. Hollinger FB and Kleinman S. Transfusion Transmission of West Nile Virus: A merging of historical and contemporary perspective. *Transfusion* 43:992-997, 2003.
244. Lerat H and Hollinger FB. HCV Occult Infection or Occult HCV RNA Detection. *J. Infect. Dis.* 189:3-6, 2004.
245. Soucie JM, Siwak EB, Hooper WC, et al. Human parvovirus B19 in young male patients with hemophilia A: associations with treatment product exposure and joint range-of-motion limitation. *Transfusion* 44:1179-1185, 2004.
246. Keasler VV, Lerat H, Madden CR, et al. Increased liver pathology in hepatitis C virus transgenic mice expressing the hepatitis B virus X protein. *Virology* 347:466-475, 2006.
247. Hollinger FB and Lau D T-Y. Hepatitis B: The pathway to recovery through treatment. In: Graham DY and Goodgame R, (eds). *Gastroenterology Clinics of North America*. Philadelphia: Elsevier Saunders Publishers, pp. 425-461, 2006.
248. Hollinger FB and Emerson SU. Hepatitis A virus. In: Knipe DM, Howley PM (eds). *Fields Virology*, 5th edition. Philadelphia: Lippincott Williams & Wilkins Publishers; pp. 911-947, 2007.
249. Nurgalieva Z, Hollinger FB, Graham DY, et al. Epidemiology and transmission of hepatitis B and C viruses in Kazakhstan. *World J Gastroenterol* 13:1204-1207, 2007.

- 250. Carr C, Hollinger FB, Yoffe B, et al. Efficacy of interferon alpha-2b induction therapy before retreatment for chronic hepatitis C. *Liver International* 27:1111-1118, 2007.
- 251. Hollinger FB, Bell B, Levy-Bruhl D, et al. Hepatitis A and B vaccination and public health. *J. Viral Hepatitis*, 14(Suppl. 1):1-5, 2007.
- 252. Hollinger FB. Hepatitis B virus genetic diversity and its impact on diagnostic assays. *J. Viral Hepatitis*, 14(Suppl. 1):11-15, 2007.
- 253. Handelsman E, Cheng I, Thompson B, et al. Impact of GB virus type C infection on mother-to-child HIV transmission in the Women and Infants Transmission Study Cohort. *HIV Medicine*, 8:561-567, 2007.
- 254. Hollinger FB. Hepatitis B virus infection and transfusion medicine: science and the occult. *Transfusion*, 48:1001-1026, 2008.
- 255. -----(b)(4)-----
-----.